

3 October 2023

Market Announcements Office  
Australian Securities Exchange

### **Shareholders vote for Board changes to bring in new skills**

ImpediMed Limited (ASX: IPD) announced the results of the General Meeting last week at which the Company's shareholders gave a strong endorsement for change, bringing new skills to the Board to support the Company to realise its long-term potential, and provide confidence to shareholders in the governance and strategy of the Company.

At the first meeting of the newly constituted Board, the Board appointed McGregor Grant as Chair. Joining McGregor are the incoming Non-Executive Directors Christine Emmanuel-Donnelly, Andrew Grant and Janelle Delaney together with Managing Director and CEO Rick Valencia and Non-Executive Director Dr Michael Seiden.

The Board would like to acknowledge the contribution of the outgoing Directors. Under the outgoing Board, ImpediMed transitioned to a company ready to commercialise. The newly configured Board is excited by the opportunity to build on all the work that has helped ImpediMed reach this stage of its journey.

In the process leading to last week's General Meeting, the incoming and existing Board members met with numerous institutional and private investors, representing a significant proportion of the Company's shareholder base. There were several clear messages that the Board will prioritise, including strong governance, the evolution, articulation and execution of strategies towards maximising shareholder value, a focus on cost management and profitable growth, and clear communication.

As a diverse, skilled and independent Board we are committed to working closely with the management team. Over the coming weeks the Board will work with management to review the Company's strategy to ensure it maximises the potential opportunities, and positions the Company for a successful transition to a high growth, highly profitable business. The Board acknowledges this process needs to be swift and will provide an update at the upcoming AGM.

Management will provide an update on the business at the upcoming September quarterly, to be held later in October.

**Approved for release by the Board of Directors.**

**About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.